NASDAQ:GOSS - Gossamer Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.83
  • Forecasted Upside: 175.10 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$8.30
▼ -0.3 (-3.49%)
1 month | 3 months | 12 months
Get New Gossamer Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GOSS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GOSS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$22.83
▲ +175.10% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Gossamer Bio in the last 3 months. The average price target is $22.83, with a high forecast of $32.00 and a low forecast of $15.00. The average price target represents a 175.10% upside from the last price of $8.30.
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Gossamer Bio.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/10/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/8/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/6/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2020

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/19/2020HC WainwrightLower Price TargetBuy$31.00 ➝ $15.00Medium
i
Rating by P. Trucchio at HC Wainwright
10/16/2020BarclaysLower Price TargetReduce ➝ Overweight$22.00 ➝ $18.00Low
i
10/13/2020SVB LeerinkLower Price TargetOutperform$36.00 ➝ $29.00High
i
10/13/2020Piper SandlerLower Price TargetOverweight$30.00 ➝ $23.00High
i
10/9/2020Cantor FitzgeraldLower Price TargetOverweight$33.00 ➝ $20.00High
i
Rating by E. Nealon at Cantor Fitzgerald
9/22/2020HC WainwrightReiterated RatingBuy$31.00Low
i
Rating by P. Trucchio at HC Wainwright
7/14/2020Cantor FitzgeraldBoost Price TargetOverweight$25.00 ➝ $33.00High
i
6/29/2020HC WainwrightInitiated CoverageBuy$31.00High
i
Rating by P. Trucchio at HC Wainwright
5/20/2020SVB LeerinkBoost Price TargetPositive ➝ Outperform$27.00 ➝ $36.00Low
i
4/22/2020Piper SandlerInitiated CoverageOverweight$30.00High
i
2/27/2020BarclaysInitiated CoverageOverweight$21.00High
i
12/17/2019Cantor FitzgeraldReiterated RatingOverweight$34.00 ➝ $25.00High
i
Rating by E. Merle at Cantor Fitzgerald
12/6/2019Cantor FitzgeraldInitiated CoverageOverweight$34.00High
i
Rating by E. Merle at Cantor Fitzgerald
12/3/2019Bank of AmericaInitiated CoverageBuy$32.00Low
i
10/30/2019Berenberg BankInitiated CoverageBuy$31.00High
i
8/12/2019Evercore ISISet Price TargetBuy$30.00Medium
i
Rating by Joshua Schimmer at Evercore ISI
3/5/2019Evercore ISIInitiated CoverageOutperform$30.00High
i
3/5/2019SVB LeerinkInitiated CoverageOutperform$30.00High
i
Rating by J. Schwartz at SVB Leerink LLC
3/5/2019BarclaysInitiated CoverageOverweight$27.00High
i
3/5/2019Bank of AmericaInitiated CoverageBuy$30.00High
i
(Data available from 10/31/2015 forward)
Gossamer Bio logo
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $8.30
$7.92
$8.50

50 Day Range

MA: $11.55
$8.60
$14.09

52 Week Range

Now: $8.30
$7.52
$27.15

Volume

1,020,642 shs

Average Volume

614,893 shs

Market Capitalization

$629.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2